(NASDAQ: CYCC) Cyclacel Pharmaceuticals's forecast annual revenue growth rate of 612.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Cyclacel Pharmaceuticals's revenue in 2024 is $449,000.On average, 1 Wall Street analysts forecast CYCC's revenue for 2026 to be $81,927,871, with the lowest CYCC revenue forecast at $81,927,871, and the highest CYCC revenue forecast at $81,927,871. On average, 1 Wall Street analysts forecast CYCC's revenue for 2027 to be $168,377,213, with the lowest CYCC revenue forecast at $168,377,213, and the highest CYCC revenue forecast at $168,377,213.
In 2028, CYCC is forecast to generate $234,311,664 in revenue, with the lowest revenue forecast at $234,311,664 and the highest revenue forecast at $234,311,664.